Ajanta Pharma shares gained 2.93% to trade at Rs 2,552.70 in Wednesday's session, driven by a surge in trading volume. The stock's performance stood out, with significant trading activity observed during the session.
Quarterly consolidated financials show a steady performance. Revenue for the quarter-ending June 2025 stood at Rs 1,302.65 Crore, up from Rs 1,170.41 Crore in March 2025. Net profit for the same period was Rs 255.34 Crore, compared to Rs 225.26 Crore in the previous quarter. The company's earnings per share (EPS) was Rs 20.44 for June 2025, an increase from Rs 18.00 in March 2025.
The following table shows the quarterly consolidated financial performance:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 1,144.92 Crore | Rs 1,186.64 Crore | Rs 1,146.13 Crore | Rs 1,170.41 Crore | Rs 1,302.65 Crore |
| Net Profit | Rs 245.77 Crore | Rs 216.48 Crore | Rs 232.88 Crore | Rs 225.26 Crore | Rs 255.34 Crore |
| EPS | 19.54 | 17.27 | 18.60 | 18.00 | 20.44 |
The annual consolidated financials indicate consistent growth. Revenue for the year-ending March 2025 reached Rs 4,648.10 Crore, compared to Rs 4,208.71 Crore in March 2024. Net profit also increased, with Rs 920.39 Crore reported for March 2025 against Rs 816.17 Crore for the previous year. The EPS was Rs 73.56 in March 2025, up from Rs 64.82 in March 2024.
The table below presents the annual consolidated financial highlights:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,889.69 Crore | Rs 3,340.99 Crore | Rs 3,742.64 Crore | Rs 4,208.71 Crore | Rs 4,648.10 Crore |
| Net Profit | Rs 653.87 Crore | Rs 712.68 Crore | Rs 587.98 Crore | Rs 816.17 Crore | Rs 920.39 Crore |
| EPS | 75.09 | 82.45 | 45.89 | 64.82 | 73.56 |
| BVPS | 344.52 | 380.24 | 268.14 | 282.34 | 302.38 |
| ROE | 21.82 | 21.83 | 17.35 | 22.87 | 24.28 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key financial ratios reflect the company's performance. Basic EPS has grown from Rs 75.09 in March 2021 to Rs 73.56 in March 2025. The book value per share has increased from Rs 344.52 in March 2021 to Rs 302.38 in March 2025. The company's return on equity (ROE) stood at 24.28% for March 2025, compared to 22.87% for March 2024. The debt-to-equity ratio remained at 0.00 over the past five years.
Ajanta Pharma shares are experiencing a volume surge, with the stock currently trading at Rs 2,552.70 on the NIFTY MIDCAP 150.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
